Procurement of non-exclusive drug rebate agreements according to § 130a para. 8 SGB V via an open-house model for the active ingredient Ustekinumab (WHO ATC code: L04AC05)

This tender, from Germany and published on TED, concerns the conclusion of an agreement, excluding specific drug rebate agreements under § 130a Abs. 8 SGB V, via an 'Open-House-Modell' for the active substance Ustekinumab (ATC code according to W...). The contracting authority is seeking to establish a framework for the supply of this pharmaceutical product. Ustekinumab is a biologic medication used for treating certain autoimmune conditions like psoriasis and Crohn's disease. The 'Open-House-Modell' likely refers to a model where multiple suppliers can participate under pre-agreed conditions. Key aspects of this procurement will involve securing a reliable supply of Ustekinumab, adhering to German pharmaceutical regulations, and potentially negotiating pricing and supply terms. Bidders will need to be authorized manufacturers or distributors of Ustekinumab. Requirements will include proof of marketing authorization, adherence to quality standards (e.g., GMP), and a commitment to supply. The focus is on ensuring patient access to this important therapy while managing costs effectively within the German healthcare system.